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Abstract 
Background: Stereotactic radiosurgery (SRS) alone is an increasingly accepted treatment for 
brain metastases, but requires adherence to frequently scheduled follow-up neuroimaging due to 
risk of distant brain metastasis. The effect of disparities in access to follow-up care on outcomes 
after SRS alone is unknown. 
Methods: This retrospective study included 153 brain metastasis patients treated consecutively 
with SRS alone from 2010 through 2016 at an academic medical center and a safety net hospital 
located in Los Angeles, California. Outcomes included neurologic symptoms, hospitalization, 
steroid use and dependency, salvage SRS, salvage whole brain radiotherapy (WBRT), salvage 
neurosurgery, and overall survival (OS). 
Results: Of 153 patients, 93 were private hospital patients and 60 were safety net hospital 
patients. Median follow-up time was 7.7 months. Safety net hospital patients received fewer 
follow-up neuroimaging studies (1.5 safety net, 3 private; p=0.008). In multivariable analysis, 
safety net hospital setting was a significant risk factor for salvage neurosurgery (HR 13.65, 
p<0.001), neurologic symptoms (HR 3.74, p=0.002), and hospitalization due to brain metastases 
(HR 6.25, p<0.001). More clinical visits were protective for hospitalization due to brain 
metastases (HR 0.75, p=0.002) while more neuroimaging studies were protective for death (HR 
0.65, p<0.001). 
Conclusions: Safety net hospital patients with brain metastases treated with SRS alone had 
fewer follow-up neuroimaging studies and higher risk of neurologic symptoms, hospitalization 
for brain metastases, and salvage neurosurgery compared to private hospital patients. Clinicians 
should consider practice setting and patient access to follow-up care when deciding on the 
optimal strategy for treatment of brain metastases. 
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Glossary 
ACS; American Community Survey 
AJCC; American Joint Committee on Cancer 
CI; Confidence interval 
CTCAE; Common Terminology Criteria for Adverse Events 
GPA; Graded Prognostic Assessment 
Gy; Gray 
HR; Hazard ratio 
IQR; Interquartile range 
KPS; Karnofsky Performance Scale 
LAC+USC; Los Angeles County + USC Medical Center 
MRI; Magnetic resonance imaging 
NCCN; National Comprehensive Cancer Network 
OS; Overall survival 
PACS; Picture archiving and communication system 
PH; Private hospital 
RCT; Randomized controlled trial 
SNH; Safety net hospital 
SRS; Stereotactic radiosurgery 
USC; University of Southern California 
WBRT; Whole brain radiation therapy  
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Introduction 
The standard of care for treatment of brain metastases has historically been whole brain 
radiation therapy (WBRT) with surgery or stereotactic radiosurgery (SRS) as adjuvant 
treatment.1 However, with improving systemic therapies and survival in patients with metastatic 
disease, there has been growing interest in treatment strategies that offer high quality of life and 
prolonged intracranial control.2 Recently, SRS alone has become an increasingly accepted 
treatment option due to improved neurocognitive preservation compared to patients treated with 
SRS and WBRT demonstrated in two randomized controlled trials (RCTs).3,4 SRS delivers a 
single, high dose of focal radiation to the tumor while sparing adjacent normal brain tissue and is 
administered in a single session. Multiple RCTs have shown no improvement in overall survival 
with the addition of WBRT to SRS.5,6 The success of SRS alone, however, depends on close 
clinical observation with neuroimaging due to the increased risk of distant brain metastasis 
failure associated with the omission of WBRT.4–6 
Unfortunately, not all patients have equal access to recommended follow-up clinical care, 
neuroimaging, and salvage treatment. Disparities in cancer outcomes and access to cancer care 
among different racial and socioeconomic groups are well recognized in the medical literature.7–
14 Patients with melanoma who have Medicaid or are uninsured are more likely to present with 
advanced disease, less likely to receive treatment, and have worse overall survival.7 Black 
patients have worse outcomes and survival in advanced breast cancer even after adjusting for 
confounding factors.8 Black and Hispanic patients are less likely to receive radiation therapy for 
locally advanced breast cancer.9 Increasing distance to the nearest urologist is associated with an 
increased chance of being diagnosed with high risk prostate cancer, but disproportionately 
affects black patients.14 
The effect of disparities in access to care on patient outcomes when utilizing a strategy of 
treating brain metastases with SRS alone, however, is unknown. As SRS becomes more widely 
utilized in diverse clinical settings and patient populations, the potential impact of demographics 
and access to care on patient outcomes will continue to grow, as will the importance of 
understanding these factors.2 Thus, in the present study, we compared clinical outcomes between 
safety net hospital (SNH) and private hospital (PH) patients treated with SRS alone to test the 
hypothesis that, due to worse neurologic outcomes, SRS alone with observation may not always 
! 6 
be suitable for patients originating from a SNH environment who may have barriers to 
appropriate follow-up care. 
 
Methods 
Study Population 
This retrospective cohort study was approved by the University of Southern California 
(USC) Keck School of Medicine Institutional Review Board. We included patients who received 
initial SRS for treatment of brain metastases at USC Norris Comprehensive Cancer Center 
(Norris, PH) or Los Angeles County + USC Medical Center (LAC+USC, SNH) from 2010-2016 
using institutional treatment databases. 
 
Setting and Patient Flow 
 Both LAC+USC and Norris are USC teaching hospitals, but each hospital has a separate 
administration. LAC+USC is the largest safety net hospital in Los Angeles County, with the 
designation of “safety net” meaning that it is legally obligated to provide medical care for 
patients regardless of their insurance status or ability to pay for services. Patients in our study 
from both hospitals were presented at the same multi-disciplinary tumor board consisting of 
neurosurgeons, radiation oncologists, and neuroradiologists, and were deemed to be candidates 
for SRS based on their clinical history and neuroimaging. 
LAC+USC patients were initially evaluated and determined to be candidates for SRS by 
the LAC+USC team. They were presented at the tumor board and referred to Norris for 
consultation with the SRS treatment team. The SRS procedure was performed at Keck Hospital 
of USC (Keck). After the SRS procedure, LAC+USC patients returned to LAC+USC for follow-
up care. 
Norris patients were initially evaluated at Norris and determined to be candidates for SRS 
by the Norris team. They were presented at the same tumor board, treated with SRS at Keck, and 
then continued their follow-up care at Norris. The recommended routine follow-up interval for 
clinical and neuroimaging visits after SRS was every 2 - 3 months at Norris and LAC+USC, 
consistent with National Comprehensive Cancer Network (NCCN) guidelines.15 
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Radiation Delivery 
All patients were treated with single-fraction Gamma Knife radiosurgery using Gamma 
Knife Perfexion (Elekta AB, Stockholm, Sweden). Patients were immobilized with a stereotactic 
head frame. The frame was affixed to the cranium of the patient while under conscious sedation. 
Magnetic resonance imaging (MRI) of the brain was performed for treatment planning and 
radiation therapy was delivered the same day. No planning target volume margins were added 
for any patients treated as all patients included in the study had intact brain metastases. 
 
Data Source and Approach 
Medical records were reviewed to obtain patient demographic information including age, 
race, sex, insurance status, and residential zip code. Household incomes were based on aggregate 
zip code data from the American Community Survey (ACS) 2014. All cancer staging was 
performed with the American Joint Committee on Cancer (AJCC) 7th edition guidelines.16 Tumor 
volumes and maximum diameters were obtained from radiation treatment planning software or 
measured manually in the institutional picture archiving and communication system (PACS). 
The number of clinical visits and neuroimaging studies included only those performed as part of 
routine follow-up. Neurologic symptoms were identified from medical records and graded using 
the Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Only neurologic 
symptoms attributable to brain metastases were included in analysis. Severe neurologic 
symptoms were defined as grade !3. Date of last follow-up was the last clinical encounter 
documented in medical records. Survival data was obtained from institutional cancer registries 
and public online databases. 
 
Statistical Analysis 
Baseline patient information, treatment characteristics, number of clinical follow-ups, 
number of neuroimaging follow-ups, steroid use and dependency, and rates of salvage treatments 
were compared with the Wilcoxon rank sum test and Pearson chi-square test. Development of 
new neurologic symptoms, hospitalizations, salvage surgery, salvage SRS, salvage WBRT, and 
overall survival (OS) were analyzed as time-dependent variables with the Kaplan-Meier method 
with time calculated from the date of first radiation treatment to the event and censoring 
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occurring either at death or date of last follow-up. Statistical significance comparisons between 
the two hospitals were calculated using the log-rank test. 
Univariate and multivariate analysis were performed with the Cox proportional hazards 
model. All risk factors, including institution, age, race, income, education, tumor histology, stage 
at diagnosis, time from brain metastasis diagnosis to SRS, clinical visits, neuroimaging studies, 
KPS, GPA, neurologic status at baseline, number of brain metastases, and total tumor volume 
were entered into univariate analysis with each clinical outcome. Risk factors with p<0.10 and 
other clinically relevant variables were further entered into multivariable analysis. Significance 
was considered p<0.05. All analysis was performed using SAS software (version 9.4; SAS 
Institute, Cary, NC) and R software (version 3; R Foundation, Vienna, Austria). 
 
Results 
176 patients received SRS consecutively for brain metastases from 2010-2016, including 
110 PH and 66 SNH patients. 6 PH (5%) and 6 SNH (9%) patients were excluded due to prior 
WBRT. 1 PH (0.9%) patient was excluded due to treatment with upfront SRS + WBRT, and 10 
PH (9%) patients were excluded due to lack follow-up after SRS treatment. In total, 153 patients 
were analyzed, including 93 PH (85%) and 60 SNH (91%) patients. 
 
Patient and Treatment Characteristics 
The median age was 59 years (IQR 50-66), 78 (51%) patients were female, and 65 (42%) 
patients were white non-Hispanic (Table 1). SNH patients were significantly younger (median 
56 years SNH; 61 years PH; p=0.001), had lower median household income ($48,754 SNH; 
$72,192 PH; p<0.001), and had lower median high school graduation rate (69.8% SNH; 88.7% 
PH; p<0.001). Of the SNH patients, 11 (18%) patients were white non-Hispanic and 32 (53%) 
were Hispanic whereas of the PH patients, 54 (58%) were white non-Hispanic and 15 (16%) 
were Hispanic (p<0.001). In addition, more SNH patients had late stage (III-IV) at diagnosis of 
cancer (91% SNH; 78% PH; p=0.04), and SNH patients had longer median time from diagnosis 
of brain metastases to SRS treatment (43 days SNH; 22 days PH; p<0.001). There was no 
significant difference between the groups in terms of KPS, graded prognostic assessment (GPA), 
baseline neurologic status, tumor histology or mutation status, prior chemotherapy or 
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neurosurgery, number of brain metastases treated, tumor location, total tumor volume, or SRS 
dose. 
 
Clinical and Neuroimaging Follow-Up 
The median follow-up time for all patients was 7.70 months. The median follow-up time 
for SNH patients was 5.93 months (IQR 2.53-15.09 months), and the median follow-up time for 
PH patients was 9.15 months (IQR 3.52-17.72 months) (p=0.09). 
SNH patients had a significantly lower absolute number and monthly rate of 
neuroimaging studies after SRS (median 1.5 and 0.228, respectively) compared to PH patients 
(median 3 and 0.312, respectively) (p=0.008 and p=0.007, respectively) (Table 2). In contrast, 
SNH patients received a similar absolute number and monthly rate of clinical visits after SRS 
(median 1.5 and 0.298, respectively) compared to PH patients (median 2 and 0.288, respectively) 
(p=0.23 and p=0.97, respectively). 
 
Incidence of Neurologic Symptoms and Salvage Treatments 
 SNH patients had significantly higher rates of any neurologic symptoms (33% SNH; 19% 
PH; p=0.05) and severe neurologic symptoms (15% SNH; 2% PH; p=0.003) following SRS 
(Table 3). SNH patients also had higher rates of hospitalization due to brain metastases (25% 
SNH; 7.5% PH; p=0.003) and salvage neurosurgery (17% SNH; 6% PH; p=0.04) following SRS. 
SNH patients did not experience significantly different rates of permanent neurologic symptoms, 
hospitalization for any reason, steroid requirement or dependency, salvage SRS, or salvage 
WBRT compared to PH patients. 
 
Univariate Analysis 
The median OS for all patients was 15.4 months. The median OS for SNH patients was 
17.5 months and the median OS for PH patients was 15.1 months (p=0.34). SNH patients had 
higher risk of developing any neurologic symptoms (hazard ratio [HR], 2.64; 95% CI, 1.35-5.17; 
p=0.003), severe neurologic symptoms (HR, 9.20; 95% CI, 1.98-42.75; p<0.001), and permanent 
neurologic symptoms (HR, 2.33; 95% CI, 1.01-5.52; p=0.05). SNH patients were at higher risk 
for salvage neurosurgery following SRS (HR, 3.29; 95% CI, 1.19-9.08; p=0.01). SNH patients 
did not have higher risk for any hospitalization (HR, 1.00; 95% CI, 0.65-1.55; p=0.99) but did 
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have higher risk for hospitalization due to brain metastasis progression (HR, 3.64; 95% CI 1.40-
9.44; p=0.005). There was no significant difference in risk of salvage SRS or salvage WBRT. 
Kaplan Meier survival curves for OS, salvage neurosurgery, any neurologic symptoms, and 
hospitalization for brain metastases are found in Figure 1. 
 
Multivariable Analysis 
On multivariable analysis, all-cause mortality was significantly associated with additional 
neuroimaging studies (HR, 0.65; 95% CI, 0.58-0.74; p<0.001), GPA (HR, 0.66; 95% CI, 0.46-
0.94; p=0.02), breast histology (HR, 1.26; 95% CI 1.02-4.73; p=0.04), and melanoma histology 
(HR, 2.91; 95% CI, 1.36-6.22; p=0.006) (Table 4). 
Significant risk factors for salvage neurosurgery included SNH setting (HR, 13.65; 95% 
CI, 3.31-56.29, p<0.001), neurologic symptoms at baseline (HR, 11.40; 95% CI, 2.82-46.12; 
p<0.001), number of brain metastases (HR, 1.26; 95% CI, 1.08-1.48; p=0.02), and melanoma 
histology (HR, 22.73; 95% CI, 3.24-159.29; p=0.002). 
Significant risk factors for development of any neurologic symptoms included SNH 
setting (HR, 3.74; 95% CI, 1.60-8.74; p=0.002), early stage at diagnosis (HR, 0.28; 95% CI, 
0.12-0.66; p=0.003), follow-up neuroimaging (HR, 0.87; 95% CI, 0.77-0.98; p=0.02), and breast 
histology (HR, 3.70; 95% CI, 1.30-10.52; p=0.01). 
Significant risk factors for hospitalization due to brain metastasis progression included 
SNH setting (HR, 6.25; 95% CI, 2.22-17.57; p<0.001), follow-up clinical visits (HR, 0.75; 95% 
CI, 0.62-0.90; p=0.002), number of brain metastases (HR, 1.32; 95% CI, 1.05-1.65; p=0.02), and 
renal histology (HR, 4.58; 95% CI, 1.12-18.72; p=0.03). 
 
Discussion 
 The goal of our study was to examine the effect of hospital setting and quality of follow-
up on neurologic outcomes in brain metastasis patients treated with SRS alone. Although it is 
currently accepted that patients undergoing SRS alone require close clinical monitoring with 
neuroimaging due to the increased distant brain metastasis failure rate with omission of WBRT, 
we are not aware of any studies that have directly correlated follow-up clinical visits and 
neuroimaging studies with clinical outcomes. Furthermore, we did not find any studies that 
examined healthcare disparities in the brain metastasis population treated with SRS, and how 
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their treatment outcomes might depend on the clinical setting and patient demographics such as 
race, household income, or insurance status. Given the unique affiliation between the SNH and 
PH as teaching hospitals with collaboration for SRS treatment, we were especially well-
positioned to carry out such a study. 
We found that following SRS, SNH patients had higher incidence of and risk for any 
neurologic symptoms, severe neurologic symptoms, hospitalizations for brain metastases, and 
salvage neurosurgeries. Despite this, SNH and PH patients had similar OS. OS was high in both 
groups compared to historic survival after a diagnosis of brain metastases, which may be 
attributed to patient selection for SRS and improving systemic therapy.17 The observation that 
SNH patients did not have worse median OS despite higher rates of neurologic symptoms and 
hospitalizations for brain metastases could be explained by excellent neurosurgical care allowing 
the successful salvage of patients with brain metastasis progression, as SNH patients also had 
higher rates of salvage neurosurgery. In addition, there may have been undetected differences in 
systemic disease burdens between the cohorts or our study may have been underpowered to 
detect differences in survival. 
Although the two patient populations differed in terms of multiple baseline factors 
including younger age, more advanced stage at diagnosis of cancer, and longer time from 
diagnosis of brain metastases to SRS treatment for SNH patients, they had similar baseline KPS, 
GPA, histology, number of brain metastases, and total tumor volume. Studies have shown that 
the strongest predictors of outcomes following treatment of brain metastases with SRS include 
age, KPS, histology, number of brain metastases, and total tumor volume – all of which, besides 
age, were similar in the two groups.18–22 Furthermore, the SNH patient population was 
significantly younger than the PH patient population, which typically confers better outcomes. 
In multivariable analysis, SNH setting remained associated with increased risk for 
salvage neurosurgery, any neurologic symptoms, and hospitalization for brain metastases even 
after controlling for multiple other risk factors including tumor histology and time from initial 
consultation to SRS treatment. In an attempt to assess the quality of follow-up for patients after 
SRS, we recorded the number of routine follow-up clinical visits and neuroimaging studies that 
patients received. In comparison to PH patients, SNH patients received similar numbers of 
follow-up clinical visits but fewer neuroimaging studies. 
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On multivariable analysis, more follow-up clinical visits was correlated with fewer 
hospitalizations for brain metastases, while more follow-up neuroimaging studies was associated 
with better OS and less risk for development of any neurologic symptoms. These findings 
indicate that the poor outcomes observed in the SNH patient group were at least partly 
attributable to receiving less neuroimaging studies after SRS. We confirm and reemphasize the 
need for close clinical and neuroimaging surveillance after a treatment strategy of SRS alone for 
brain metastases. The comparatively smaller effect magnitude of clinical and neuroimaging 
follow-ups on these outcomes compared to SNH setting could potentially be due to challenges in 
quantifying the quality of follow-up, such as differentiating symptom-triggered visits from 
routine visits, accounting for differences in clinical follow-ups due to varying systemic therapy 
regimens, and determining whether patients received care at institutions outside our healthcare 
network.23 Nonetheless, our results suggest that there may be other unaccounted for risk factors 
associated with a SNH practice setting, such as more patient comorbidities, less access to and 
compliance with systemic therapies, fewer hospital resources, and lower quality of medical 
care.24–27 
There are numerous possible explanations for the disparity in number of neuroimaging 
follow-ups at the two hospitals, including differences in age, race, income, education, language, 
social supports, distance from treatment center, access to transportation, ability to take time off 
from work, and severity of disease.24 The fact that SNH patients still received similar clinical 
follow-up implies that the underlying reason(s) are either specific to neuroimaging or affect 
compliance with neuroimaging studies more than clinical visits. An institution-specific barrier 
that we identified is the number of MRI scanners available. LAC+USC, which has 650 hospital 
beds, has three 1.5 Tesla MRI scanners whereas Keck Hospital, which has 471 hospital beds, has 
two 1.5 Tesla and three 3 Tesla MRI scanners (5 total) available for patient use. There is a 
general consensus among providers at our institutions that there are longer scheduling wait times 
for neuroimaging appointments at LAC+USC. Currently, LAC+USC has a >4 month backlog, 
defined as the time between the date the exam is ordered and the date of the neuroimaging 
appointment, whereas Keck Hospital has no backlog or waiting queue for scheduling 
neuroimaging appointments. 
The finding that increasing number of brain metastases was associated with increased risk 
for salvage neurosurgery and hospitalization for brain metastases is consistent with other 
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analyses that found number of brain metastases to be a significant prognostic factor after 
treatment with SRS.18–21 These studies focused on the effect of number of brain metastases on 
OS, but we now report that it may have prognostic significance for other neurologic outcomes 
such as salvage neurosurgery and hospitalization as well. Given that SNH and PH patients had 
similar numbers of brain metastases, this factor alone did not explain the difference in neurologic 
outcomes. 
 
Limitations 
 The main limitations of our study are its retrospective nature, relatively small sample 
size, and heterogeneous cohorts. Patients at the PH and SNH had significantly different baseline 
characteristics that we attempted to account for in multivariable analysis. There were challenges 
in quantifying the quality of follow-up that may have lessened the true magnitude of effect on 
outcomes. Neurologic symptoms were determined retrospectively and thus were less reliable 
than a prospective study with real time data on neurologic status. Despite this, it is unlikely that 
the observed differences in neurologic outcomes between the hospitals can be accounted for 
merely by retrospective bias. 
 
Conclusions 
Brain metastasis patients followed in a SNH setting after treatment with SRS alone 
experienced higher rates of neurologic symptoms, severe neurologic symptoms, hospitalizations 
for brain metastases, and salvage neurosurgeries compared to PH patients. During follow-up, 
SNH patients received fewer neuroimaging studies. In multivariable analysis, early stage at 
diagnosis, more neuroimaging studies, and more clinical visits were protective for neurologic 
outcomes whereas SNH setting and higher number of brain metastases were risk factors for poor 
neurologic outcomes. 
The treatment strategy of SRS alone with observation for brain metastases may be 
challenging to perform in the SNH setting due to fewer follow-up neuroimaging studies and 
other unidentified barriers associated with practice in a SNH setting. Patients and clinicians 
should consider patient access to follow-up care when deciding on the optimal strategy for 
treatment of brain metastases.  
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Suggestions for Future Work 
Our study was conducted jointly at Norris, an academic medical center, and LAC+USC, 
one of the largest safety net hospitals in the United States, both located in Los Angeles, 
California. The results may or may not be generalizable to other practice settings where indigent 
patients are managed. Therefore, further study in this area at other indigent care settings is 
needed to confirm our findings. Additional studies are also needed to identify potential barriers 
to receiving appropriate brain metastasis follow-up care after SRS alone and potential 
interventions to improve compliance rates and neurologic outcomes in this setting. Our center 
plans to investigate the impact that a resident-led radiation oncology continuity clinic will have 
on patient compliance and outcomes after SRS alone. 
  
Summary 
 In this retrospective cohort study of 153 patients with brain metastases, safety net hospital 
patients, as compared to private hospital patients, received fewer total follow-up neuroimaging 
studies (median 1.5 safety net vs. 3 private) and had higher rates of severe neurologic symptoms 
(15% safety net vs. 2% private), hospitalizations due to brain metastases (25% safety net vs. 
7.5% private), and salvage neurosurgery (17% safety net vs. 6% private) following radiosurgery 
alone. Clinicians should consider practice setting and patient access to follow-up care when 
deciding on the optimal strategy for treatment of brain metastases. 
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Table 1. Baseline Patient and Treatment Characteristics 
 Private (n=93) Safety Net (n=60) All (n=153) p-value 
Age, median (IQR) 61 (53-69) 56 (46-63) 59 (50-66) 0.001 
Sex    0.14 
  Male 50 (54%) 25 (42%) 75 (49%)  
  Female 43 (46%) 35 (58%) 78 (51%)  
Race    <0.001 
  White non-Hispanic 54 (58%) 11 (18%) 65 (42%)  
  Hispanic (any race) 15 (16%) 32 (53%) 47 (31%)  
  Asian non-Hispanic 17 (18%) 7 (17%) 24 (16%)  
  Black non-Hispanic or 
Other 
7 (8%) 10 (12%) 17 (11%)  
Insurance status    <0.001 
  Private/managed 
care/Medicare 
87 (94%) 8 (13%) 95 (62%)  
  Medicaid, uninsured, or 
other 
6 (6%) 52 (87%) 58 (38%)  
Household income, median 
(IQR) 
72192 (50574-
92960) 
48754 (35693-
60167) 
59099 (43385-
80864) 
<0.001 
KPS, median (IQR) 80 (75-90) 80 (80-90) 80 (80-90) 0.23 
GPA, median (IQR) 1.5 (1-2) 1.75 (1-2.5) 1.5 (1-2.25) 0.67 
Neurologically symptomatic 
at baseline 
35 (38%) 23 (38%) 58 (38%) 0.93 
Tumor histology    0.17 
  Lung adenocarcinoma 22 (24%) 21 (35%) 43 (28%)  
    EGFR mutation 7 (35%) 4 (25%) 11 (31%) 0.52 
    ALK mutation 4 (20%) 3 (19%) 7 (19%) 0.93 
  Breast adenocarcinoma 11 (12%) 9 (15%) 20 (13%)  
  Melanoma 16 (17%) 3 (5%) 19 (12%)  
    BRAF mutation 6 (40%) 2 (67%) 8 (44%) 0.40 
  Renal cell carcinoma 13 (14%) 8 (13%) 21 (14%)  
  Other 31 (33%) 19 (32%) 50 (33%)  
Stage at diagnosis    0.04 
  Stage 1-2 18 (22%) 5 (9%) 23 (16%)  
  Stage 3-4 65 (78%) 52 (91%) 117 (84%)  ! !
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Table 1 Continued 
 Private (n=93) Safety Net (n=60) All (n=153) p-value 
Brain metastases diagnosed 
within 3 months of primary 
28 (30%) 27 (45%) 55 0.06 
Prior surgical resection of 
brain metastases 
41 (44%) 21 (35%) 62 0.26 
Prior systemic therapy 87 (94%) 53 (88%) 140 0.26 
Time from initial 
consultation to SRS, days, 
median (IQR) 
9 (5-15) 24 (16.5-37) 15 (7-25) <0.001 
Time from brain metastases 
diagnosis to SRS, days, 
median (IQR) 
22 (13.5-48.5) 43 (33-73.8) 33 (17-59) <0.001 
Number of brain metastases 
treated, median (IQR) 
2 (1-3) 2 (1-4) 2 (1-3) 0.64 
Total tumor volume, cc, 
median (IQR) 
4.90 (1.33-10.07) 4.96 (1.61-9.79) 4.90 (1.46-9.93) 0.78 
Total treatment volume, cc, 
median (IQR) 
6.61 (1.84-13.76) 7.05 (2.68-13.82) 6.7 (2.10-13.73) 0.73 
SRS dose, Gy, median 
(IQR) 
20 (18-20) 20 (18-20) 20 (18-20) 0.73 
Tumor location    0.19 
  Cerebral hemisphere 183 (76%) 132 (82%) 315 (79%)  
  Cerebellum 40 (17%) 24 (15%) 64 (16%)  
  Other 17 (7%) 5 (3%) 22 (5%)  
Abbreviations: IQR, interquartile range; KPS, Karnofsky Performance Status; GPA, graded prognostic assessment 
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Table 2. Clinical and Neuroimaging Follow-up 
 Private (n=93) Safety Net (n=60) p-value 
Number of neuroimaging follow-ups, 
median (IQR) 
3 (1-6) 1.5 (1-4) 0.008 
Neuroimaging follow-ups per month, 
median (IQR) 
0.312 (0.201-0.418) 0.228 (0.102-0.304) 0.007 
Number of clinical follow-ups, median 
(IQR) 
2 (1-5) 1.5 (1-3) 0.23 
Clinical follow-ups per month, median 
(IQR) 
0.288 (0.092-0.401) 0.298 (0.115-0.416) 0.97 
Abbreviations: IQR, interquartile range 
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Table 3. Incidence of Neurologic Symptoms and Salvage Treatments 
 Private (n=93) Safety Net (n=60) p-value 
Developed any neurologic symptoms 18 (19%) 20 (33%) 0.05 
Developed severe neurologic symptoms 2 (2%) 9 (15%) 0.007 
Permanent neurologic symptoms 10 (11%) 11 (18%) 0.18 
Required steroids 33 (35%) 22 (37%) 0.88 
Steroid dependencya 26 (28%) 17 (28%) 0.96 
Hospitalization for any reasonb 56 (60%) 33 (55%) 0.41 
Hospitalization due to brain metastases 7 (7.5%) 15 (25%) <0.001 
Salvage neurosurgery 6 (6%) 10 (17%) 0.04 
Salvage SRS 31 (33%) 15 (25%) 0.27 
Salvage WBRT 19 (20%) 15 (25%) 0.51 
aDefined as >2 weeks 
bOther than scheduled chemotherapy or surgery admissions 
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Table 4. Multivariate Models with Significant Risk Factors 
Risk Factor Unadjusted HR (95% CI) p-value Adjusted HR (95% CI) p-value 
 Overall Survival 
Additional neuroimaging 
follow-up 
0.655 (0.583-0.737) <0.001 0.653 (0.578-0.739) <0.001 
GPA 0.657 (0.481-0.896) 0.008 0.656 (0.460-0.935) 0.02 
Additional day from 
consultation to SRS 
1.003 (0.994-1.011)  0.52 0.999 (0.989, 1.009) 0.83 
Tumor histology     
  Lung adenocarcinoma Ref. Ref. Ref. Ref. 
  Breast adenocarcinoma 1.261 (0.599-2.652) 0.54 2.199 (1.023-4.726) 0.04 
  Melanoma 1.526 (0.725-3.211) 0.27 2.912 (1.363-6.224) 0.006 
  Renal cell carcinoma 1.256 (0.597-2.644) 0.55 1.545 (0.730-3.273) 0.26 
  Other 1.623 (0.887-2.972) 0.12 1.496 (0.808-2.773) 0.20 
 Salvage Neurosurgery 
Safety net hospital 3.293 (1.194-9.082) 0.02 13.65 (3.311-56.29) <0.001 
Neurologic symptoms at 
baseline 
3.313 (1.218-9.012) 0.02 11.40 (2.819-46.12) <0.001 
Additional brain 
metastasis 
1.155 (1.002-1.332) 0.05 1.260 (1.074-1.478) 0.005 
Additional day from 
consultation to SRS 
1.001 (0.980,1.022) 0.96 0.994 (0.955-1.036) 0.79 
Tumor histology     
  Lung adenocarcinoma Ref. Ref. Ref. Ref. 
  Breast adenocarcinoma 1.023 (0.092-11.29) 0.99 0.493 (0.039-6.207) 0.58 
  Melanoma 7.082 (1.368-36.68) 0.02 22.73 (3.244-159.29) 0.002 
  Renal cell carcinoma 3.402 (0.567-20.41) 0.18 5.763 (0.907-36.64) 0.06 
  Other 3.537 (0.679-18.41) 0.13 4.250 (0.790-22.87) 0.09 
 Any Neurologic Symptoms 
Safety net hospital 2.644 (1.352-5.172) 0.004 3.739 (1.599-8.743) 0.002 
Early stage (1-2) at 
diagnosis 
0.377 (0.183-0.774) 0.008 0.280 (0.120-0.656) 0.003 
Additional neuroimaging 
follow-up 
0.859 (0.759-0.972) 0.02 0.865 (0.766-0.977) 0.02 
Additional day from 
consultation to SRS 
0.997 (0.980-1.014) 0.70 0.979 (0.957-1.002) 0.08 
Tumor histology     
  Lung adenocarcinoma Ref. Ref. Ref. Ref. 
  Breast adenocarcinoma 3.103 (1.120-8.598) 0.03 3.702 (1.303-10.52) 0.01 
  Melanoma 2.162 (0.724-6.456) 0.17 2.851 (0.915-8.877) 0.07 
  Renal cell carcinoma 1.412 (0.446-4.468) 0.56 2.301 (0.720-7.360) 0.16 
  Other 1.922 (0.712-5.190) 0.20 1.470 (0.532-4.061) 0.46 
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Table 4 Continued 
 Hospitalization for Brain Metastases 
Safety net hospital 4.371 (1.693-11.29) 0.002 6.248 (2.222-17.57) <0.001 
Additional clinical 
follow-up 
0.786 (0.659-0.937) 0.007 0.749 (0.622-0.902) 0.002 
Additional brain 
metastasis 
1.216 (1.003-1.474) 0.46 1.316 (1.052-1.647) 0.02 
Additional day from 
consultation to SRS 
1.000 (0.984-1.017) 0.971 0.988 (0.958-1.018) 0.42 
Tumor histology     
  Lung adenocarcinoma Ref. Ref. Ref. Ref. 
  Breast adenocarcinoma 1.183 (0.283-4.959) 0.82 2.585 (0.576-11.60) 0.22 
  Melanoma 2.592 (0.689-9.746) 0.16 3.360 (0.875-12.90) 0.08 
  Renal cell carcinoma 2.948 (0.777-11.18) 0.11 4.584 (1.122-18.72) 0.03 
  Other 1.570 (0.450-5.471) 0.48 2.831 (0.727-11.02) 0.13 
Abbreviations: HR, hazard ratio; CI, confidence interval; GPA, graded prognostic assessment!
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Figure 1: Kaplan Meier survival curves for (A) overall survival, (B) freedom from salvage 
neurosurgery, (C) freedom from any neurologic symptoms, and (D) freedom from hospitalization 
due to brain metastases stratified by hospital setting. 
